

## PRESS RELEASE

### Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA

(Oxford, UK and Conshohocken, US, 26 October 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that Chief Executive Officer Andrew Hotchkiss has been appointed to the Board of The BioIndustry Association (BIA).

The BIA is the trade association for innovative life sciences in the UK. The BIA's goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

**Andrew Hotchkiss, CEO of Immunocore, added:** *"The BIA plays a crucial role in representing the interests of some of the UK's most promising companies and championing the UK as a leader in the research, development and commercialisation of cutting edge biotechnologies. It is an honour to be elected to the Board and I look forward to working alongside my fellow Board members as well as the BIA's diverse membership in order to help further develop and promote the UK life sciences sector."*

- Ends -

#### For more information, please contact:

##### Immunocore

Zoe Roberts, Communications Manager

T: +44 (0)1235 438600

E: [info@immunocore.com](mailto:info@immunocore.com)

Follow on Twitter: [@Immunocore](https://twitter.com/Immunocore)

##### Consilium Strategic Communications (corporate and financial)

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh

T: +44 (0)203 709 5700

E: [Immunocore@consilium-comms.com](mailto:Immunocore@consilium-comms.com)

##### About Immunocore

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company's primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead program, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The Company is privately held by a broad international investor base. For more information, please visit [www.immunocore.com](http://www.immunocore.com).

## **About the BIA**

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

For further information, please go to [www.bioindustry.org](http://www.bioindustry.org) and [twitter.com/BIA\\_UK](https://twitter.com/BIA_UK)